



HCA Healthcare, Inc. (HCA)

Updated July 31st, 2025 by Samuel Smith

Key Metrics

Current Price:	\$354	5 Year CAGR Estimate:	11.7%	Market Cap:	\$85 B
Fair Value Price:	\$393	5 Year Growth Estimate:	8.8%	Ex-Dividend Date:	9/16/25 ¹
% Fair Value:	90%	5 Year Valuation Multiple Estimate:	2.1%	Dividend Payment Date:	9/30/25 ²
Dividend Yield:	0.8%	5 Year Price Target	\$600	Years Of Dividend Growth:	5
Dividend Risk Score:	C	Sector:	Health Care	Rating:	Hold

Overview & Current Events

HCA Healthcare, Inc., founded in 1968 and headquartered in Nashville, Tennessee, is one of the nation's leading providers of healthcare services. It owns and operates nearly 200 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers, and physician clinics across 20 U.S. states and the United Kingdom. The company employs about 271,000 people, including 94,000 registered nurses and 38,000 active physicians.

On July 25, 2025, HCA Healthcare, Inc. reported its financial results for the second quarter of 2025. HCA Healthcare reported strong financial results for Q2 2025, with revenues increasing 6.4% to \$18.605 billion compared to \$17.492 billion in Q2 2024. Net income attributable to HCA Healthcare, Inc. rose 13.1% to \$1.653 billion, with diluted earnings per share up 23.5% to \$6.83 and adjusted diluted earnings per share increasing 24.4% to \$6.84. Adjusted EBITDA grew 8.4% to \$3.849 billion, reflecting improved margins. Cash flows from operating activities surged to \$4.210 billion from \$1.971 billion in the prior year. Same facility admissions and equivalent admissions increased by 1.8% and 1.7%, respectively, though inpatient and outpatient surgeries saw slight declines of 0.3% and 0.6%. Revenue per equivalent admission rose 4.0%.

CEO Sam Hazen highlighted solid revenue growth, improved margins, and better patient outcomes, crediting the team's efforts. The company repurchased 7.031 million shares for \$2.505 billion and declared a \$0.72 per share quarterly dividend, payable September 30, 2025. Balance sheet figures included \$939 million in cash, \$44.483 billion in total debt, and \$59.536 billion in total assets. Capital expenditures for Q2 were \$1.176 billion. HCA raised its 2025 guidance, projecting revenues of \$74.00 to \$76.00 billion, net income of \$6.11 to \$6.48 billion, and adjusted EBITDA of \$14.70 to \$15.30 billion, with diluted EPS expected at \$25.50 to \$27.00.

Growth on a Per-Share Basis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
EPS	\$5.56	\$6.87	\$6.81	\$9.77	\$10.50	\$11.61	\$17.50	\$16.89	\$19.01	\$21.96	\$26.18	\$40.00
DPS	\$0.00	\$0.00	\$0.00	\$1.40	\$1.63	\$0.43	\$1.92	\$2.24	\$2.40	\$2.64	\$2.88	\$3.60
Shares	397.0	370.2	349.9	342.4	338.4	339.9	303.6	277.0	264.5	248.3	241.9	235.0

HCA Healthcare is positioned for strong growth over the next five years, with earnings per share expected to rise from \$26.18 to \$40, driven by expanding patient volumes, strategic acquisitions, and operational efficiencies. Dividends per share are projected to increase from \$2.88 to \$3.60, reflecting confidence in sustained cash flow generation. HCA's extensive hospital network, investments in technology, and focus on cost management should enhance profitability. While regulatory changes and labor costs pose risks, the company's scale, strong payer relationships, and demand for healthcare services position it well for continued revenue and earnings expansion, supporting shareholder returns.

¹ Estimate

² Estimate

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



HCA Healthcare, Inc. (HCA)

Updated July 31st, 2025 by Samuel Smith

Valuation Analysis

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	Now	2030
Avg. P/E	13.1	10.2	11.3	11.0	11.9	10.4	12.1	12.9	13.7	15.3	13.5	15.0
Avg. Yld.	0.0%	0.0%	0.0%	1.3%	1.3%	0.4%	0.9%	1.0%	0.9%	0.8%	0.8%	0.6%

HCA is currently trading at a P/E ratio of 13.5, near its 10-year historical average of 13.7 but above its long-term lows. The company's P/E has steadily expanded, reflecting investor confidence in its earnings stability and growth potential. The dividend yield of 0.8% remains low, as HCA prioritizes reinvestment and share buybacks over large dividend payouts. Over the next five years, if earnings continue growing steadily, the P/E ratio could range between 14-16, aligning with historical trends. However, if regulatory pressures or reimbursement challenges emerge, the multiple may stay closer to 12-14, limiting valuation expansion.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2030
Payout	0%	0%	0%	14%	16%	4%	11%	13%	13%	12%	11%	9%


HCA's competitive advantage lies in its extensive hospital network, scale, and operational efficiency, allowing it to negotiate favorable payer contracts and optimize costs. As the largest for-profit hospital operator in the U.S., it benefits from economies of scale and strong demand for healthcare services. During the Great Recession, HCA's earnings remained stable due to the non-discretionary nature of healthcare, though margin pressure was evident. The COVID-19 pandemic created short-term disruptions, but demand rebounded quickly as elective procedures resumed, demonstrating the company's resilience in economic downturns.

HCA maintains a healthy balance sheet with manageable debt and strong interest coverage, ensuring financial flexibility. The payout ratio has remained conservative, peaking at 16% in 2019 and stabilizing around 12% in recent years, reflecting the company's preference for reinvestment. With continued earnings growth, the payout could remain near 10-12%, ensuring dividend sustainability while allowing capital to be directed toward expansion and acquisitions. HCA's focus on cost control and strategic investments supports long-term shareholder value despite its modest yield.

Final Thoughts & Recommendation

Between its 0.8% dividend yield, 8.8% expected five-year EPS CAGR, and 2.1% expected five-year valuation multiple CAGR, we project an 11.7% annualized total return for HCA over the next half-decade, making it a Hold at the moment.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



HCA Healthcare, Inc. (HCA)

Updated July 31st, 2025 by Samuel Smith

Income Statement Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Revenue	39,678	41,490	43,614	46,677	51,336	51,533	58,752	60,233	64,968	70,603
Gross Profit	33,040	34,557	36,298	38,953	42,855	43,164	49,271	50,862	55,066	59,848
Gross Margin	83.3%	83.3%	83.2%	83.5%	83.5%	83.8%	83.9%	84.4%	84.8%	84.8%
SG&A Exp.	18,115	18,897	20,059	21,425	23,560	23,874	26,779	27,685	29,487	31,170
D&A Exp.	1,904	1,966	2,131	2,278	2,596	2,721	2,853	2,969	3,077	3,312
Operating Profit	5,965	6,198	6,057	6,642	7,218	7,262	9,678	9,053	9,627	10,547
Operating Margin	15.0%	14.9%	13.9%	14.2%	14.1%	14.1%	16.5%	15.0%	14.8%	14.9%
Net Profit	2,129	2,890	2,216	3,787	3,505	3,754	6,956	5,643	5,242	5,760
Net Margin	5.4%	7.0%	5.1%	8.1%	6.8%	7.3%	11.8%	9.4%	8.1%	8.2%
Free Cash Flow	2,359	2,893	2,411	3,188	3,444	6,397	5,382	4,127	4,687	5,639
Income Tax	1,261	1,378	1,638	946	1,099	1,043	2,112	1,746	1,615	1,866

Balance Sheet Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	32,744	33,758	36,593	39,207	45,058	47,490	50,742	52,438	56,211	59,513
Cash & Equivalents	741	646	732	502	621	1,793	1,451	908	935	1,933
Accounts Receivable	5,889	5,826	6,501	6,789	7,380	7,051	8,095	8,891	9,958	10,751
Inventories	1,439	1,503	1,573	1,732	1,849	2,025	1,986	2,068	2,021	1,738
Goodwill & Int. Ass.	6,731	6,704	7,394	7,953	8,269	8,578	9,540	9,653	9,945	10,093
Total Liabilities	38,790	39,391	41,588	42,125	45,623	44,598	49,253	52,511	55,151	58,958
Accounts Payable	2,170	2,318	2,606	2,577	2,905	3,535	4,111	4,239	4,233	4,276
Long-Term Debt	30,488	31,376	33,058	32,821	33,722	31,004	34,579	38,084	39,593	43,031
Shareholder's Equity	(7,599)	(7,302)	(6,806)	(4,950)	(2,808)	572	(933)	(2,767)	(1,774)	(2,499)
LTD/E Ratio	(4.01)	(4.30)	(4.86)	(6.63)	(12.01)	54.20	(37.06)	(13.76)	(22.32)	(17.22)

Profitability & Per Share Metrics

Year	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Assets	6.7%	8.7%	6.3%	10.0%	8.3%	8.1%	14.2%	10.9%	9.6%	10.0%
Return on Equity						322.6%	317.6%	797.0%	1062%	713.3%
ROIC	9.0%	11.5%	8.2%	13.1%	11.1%	11.2%	19.9%	15.2%	13.3%	13.7%
Shares Out.	397.0	370.2	349.9	342.4	338.4	339.9	303.6	277.0	264.5	248.3
Revenue/Share	92.98	104.81	117.17	131.37	147.42	149.98	178.71	204.41	235.04	269.68
FCF/Share	5.53	7.31	6.48	8.97	9.89	18.62	16.37	14.01	16.96	21.54

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.